NYSE
374.15USD
-2.61 (-0.69%)
We have scored 24 news catalysts on West Pharmaceutical Services, Inc. (WST) over the past 12 months. The biggest single-day move next to one of them came Oct 23, 2025, when WST closed +10.9%: “S&P500 and Dow Jones: Energy and Tech Lead Gains in US Stock Market Rebalancing”. Coverage across the window leans positive (average ticker sentiment +0.42). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
26.4B
P/E
—
EPS
—
Beta
1.14
52W range
223.83-386
Day range
367.63–381.16
Open
379.02
Prev close
376.76
Volume
182.2K
Avg volume
691.6K
Dividend
0.88
IPO
1980-03-17
Analysts publish price targets on WST, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
7 analyst price targets from $365 to $447
as of 2026-09-10
The market is 18% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about West Pharmaceutical Services, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for WST: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
The price sits at the very bottom of six published analyst targets, rejecting the 16-33% upside they see and implying the market does not believe the growth acceleration the stock's valuation requires.
What the disagreement turns on
Can Proprietary Product revenue actually accelerate from 6.8% toward the 17.9% the price requires, or is the market overpaying for a growth trajectory the company has not yet delivered? Unit volume data is wired and can test this, but pricing and margin mix cannot be measured with the tools available.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $337 on 2026-09-10 — the quote has since moved +11%, so read this as a record of what was priced in then, not now.
